Infectious diseases

Acute bacterial skin and skin structure infections

US landscape assessment of acute bacterial skin and skin structure infections (ABSSSI) and osteomyelitis
Local market adaptations of economic models in ABSSSI

COVID-19

Estimation of return on investment from vaccinating the adult population against COVID-19
Anti-viral systematic literature reviews and dossiers on COVID-19

Dengue disease

Payer slide deck to support HE models in dengue fever
Systematic literature reviews and global value dossiers in dengue fever
Development of a global value dossier in dengue fever
Systematic literature review of dengue fever in Mexico
Global value dossier on dengue fever
Finalization and validation of a PRO instrument for measurement of burden in Dengue disease

Diptheria

Burden of disease literature review on diptheria in the UK and Ireland

Ear infections and acute otitis media

Value communication support in acute otitis media associated with respiratory syncytial virus (RSV)
Diary of a caregiver validation for ear infection using the standard methodology
Training and manuscripts on the acute otitis media caregiver diary
Quality of life impact of otitis media and associated productivity loss in Malaysia and South Korea

Fungal infections

Strategic review of the key clinical and health outcomes evidence available/planned for an antifungal medication in order to perform a message audit for each key economic value message (including identification of evidence gaps)
Global value dossier and value story for a product in fungal infections
Simultaneous development and regulatory documentation of two PRO questionnaires to assess the signs and symptoms of interdigital tinea pedis and rosacea
Cost-effectiveness analysis of an antifungal drug in Sweden
Adaptation of a model on an antifungal medication for the USA and UK
Simultaneous development and regulatory documentation of two PRO questionnaires to assess the signs and symptoms of interdigital tinea pedis and rosacea

Hepatitis

Hepatitis A

Update to payer value deck in Hepatitis A
Payer material development for vaccines in hepatitis A
e-v@luate platform on vaccines for hepatitis A
Burden of disease literature review on hepatitis A in the UK and Ireland

Hepatitis B

Systematic literature review of a treatment for chronic hepatitis B
Preparation of a NICE submission for a hepatitis B drug
SMC submission for a treatment for chronic hepatitis B
Database analysis to calculate the economic burden of hepatitis B in the UK

Hepatitis C

Therapeutic area strategy analysis and reporting in chronic hepatitis C virus
Biomarkers in the treatment of hepatitis C virus infected patients – personalised medicine
Maximizing the use of a treatment for hepatitis C-infected patients through personalised medicine – extending the tool to additional treatments
Treatment algorithm for hepatitis C treatment
One-pager value communication tool for Hepatitis C
Comprehensive literature research in chronic hepatitis C in Asian countries
Database development and analysis in hepatitis C
Concept elicitation and cognitive debriefing interviews with hepatitis C patients in multiple countries
Development of an EMA summary document for several instruments used in hepatitis C trials
Development of a PRO outcomes summary document and communications support in hepatitis C trials
Description, interpretation and analysis of pooled data related to the use of several questionnaires, scales and screening tests in three hepatitis C clinical trials
Conceptual model for patients with hepatitis C
Psychometric validation of a hepatitis C symptom checklist using phase III trial data
Treatment patterns, healthcare utilization and costs associated with the hepatitis C virus in Japan
Selection of PRO measures for hepatitis C trials

Herpes zoster (shingles)

Payer communications on herpes zoster
Payer communications on a herpes zoster vaccine
A review of HTA guidance in nine countries to determine requirements for indirect costs in herpes zoster
Review of cost-effectiveness studies in post-herpetic neuralgia (PHN)
PRO literature review, instrumentation, gap analysis and recommendations in herpes zoster and post-herpetic neuralgia (PHN)
Development of a conference abstract and poster on herpes zoster and post-herpetic neuralgia
Development of two manuscripts on a herpes zoster study
Literature review investigating the burden of disease of herpes zoster and post-herpetic neuralgia in Europe
Systematic literature review on the caregiver burden in herpes zoster (shingles) and post-herpetic neuralgia
Searches to update a critical review of evidence documenting the humanistic, economic and societal burden of herpes zoster in Europe
Research study on the impact on quality of life in herpes zoster
Systematic literature review report on herpes zoster
Validation of the Numerical Rating Scale (NRS) in post-herpetic neuralgia
Payer material development for vaccines in shingles
e-v@luate platform on vaccines for shingles

Human immunodeficiency virus (HIV) / Acquired immune deficiency syndrome (AIDS)

Business planning toolkit in HIV
Development of a payer value story in HIV
Payer value story briefing document in HIV
Review of an economic model for HIV and submission to the SMC
Budget impact model in HIV
Targeted literature review of adherence in HIV
Targeted literature review in HIV and inflammation
Targeted literature synthesis of viral blips and viremia in patients with HIV
Literature review on inflammation in patients with HIV
Consulting in a multinational case-control study: Impact of side effects on the quality of life (QoL) of HIV patients
Advisory board consultation regarding product status and development in HIV
General consultancy on PRO endpoints in HIV/AIDS trials
Recommendations for the inclusion of PROs into HIV trials
Development of an expert report and FDA meeting on tolerability in HIV
Consulting on the development of a PRO strategy for international HIV trials with interviews in the US and Puerto Rico
Consulting on study documents and development of SAP for psychometric validation of a PRO instrument of tolerability in patients with HIV
Preparation and development of a manuscript on HIV Patient Symptom Profile (HIV PSP)
Preliminary psychometric validation of the HIV PSP questionnaire using the UK SWITCH study data
Analysis of HIV PSP data from the SWITCH study to compare treatment arms
Confirming concept definitions of the HIV Treatment Tolerability Index for translation purposes
An evidence synthesis on the efficacy and safety of two drugs and protease inhibitors in treatment‑naïve HIV patients
Manuscript network meta-analysis of an antiretroviral drug for the treatment of HIV
Budget impact tool for an antiretroviral drug for treatment-naive HIV
Literature review of the epidemiology and burden of illness in HIV-related neuropathy
Top-up literature review, revised manuscript and presentations on HIV and AIDS
Development and psychometric validation of a PRO instrument of tolerability in patients with HIV
Two abstracts, two posters and a manuscript on the development and psychometric validation of a PRO instrument of tolerability in patients with HIV
Selection of PRO measures for HIV trials

Human papillomavirus (HPV)

Value cards for human papillomavirus (HPV)
Payer value deck and frequently asked questions for HPV and HPV-related diseases
Value pack for a HPV vaccine
Brief adaptation of a Markov model for a HPV vaccine
Update of a budget impact model for a HPV vaccine
Cost-effectiveness analysis of a HPV vaccine for Spain
HPV vaccination impact model in infectious diseases
HTA submission for a HPV vaccine
Manuscript on the German cost-effectiveness analysis of a HPV vaccine
Manuscript on the Spanish cost-effectiveness analysis of a HPV vaccine
Systematic literature review on the indirect protection from the HPV vaccination
Value demonstration and implementation plan for a new HPV test
Training sales reps on an interactive model for a HPV vaccine
Analysis and reporting on the budget impact of a HPV vaccine
One-pager communication tool on cross-protection in HPV
One-pager on HPV in head and neck cancer
Revision of one-pagers in HPV vaccines
Literature review of epidemiology and economic data in HPV
Update to European one-pager value communication tools for HPV and for a nine-valent HPV vaccine
e-v@luate platform for HPV vaccines
Update to a payer value deck in HPV infection
Evidence package (literature review and value messages) for HPV vaccination
Adaptation of a Markov model on a HPV vaccine to Belgium
Development of a rationale for the need for a HPV vaccine
Development of an evidence compendium for HPV-related head and neck cancers
One-pager value communication on discounting approaches to HPV vaccination
Global value dossier modules for HPV vaccination cohorts
Anthropological study on the impact of HPV-related diseases
Manuscript on a HPV vaccine acceptance study in middle aged persons
Value communications for HPV immunisation data systems
Targeted literature review on a HPV vaccine to support development of a payer value deck and e-v@luate platform
Value communications development and strategic consultancy for HPV communication strategy
Value communications support and manuscript on the burden of HPV-related diseases in men globally
Global value dossier on an alternative dosing schedule in HPV
Workshop on an alternative dosing schedule in HPV
HPV dossiers workshops and value message development
One-pager on HPV-related head and neck cancer
Development of a PRO strategy in cervical cancer and HPV
Summary report, top-up literature review, meta-analysis, editorial board and manuscripts on HPV infection and cervical cancer

Influenza

Upgrade of current model-structure and sensitivity analysis in influenza
Adaptation of a cost effectiveness model for an influenza vaccine for Germany, Austria and Mexico
Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
Update of a value dossier on an influenza vaccine
Cost-effectiveness analysis of an influenza vaccine
Modification of the SIR dynamic model to the SEIR model for the USA and Italy
Modelling of influenza coverage rates
Communication of influenza coverage rates within the European Union
Book chapter written on the economics of influenza
Review of influenza vaccine uptake data
Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
Economic evaluation of a workplace influenza vaccination in Russia
Communication of the economics of an influenza vaccine
Interactive model on influenza
Adaptation of an influenza vaccine model to Belgium
Positioning paper on influenza
Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
Literature research and reporting on epidemiology and the economic burden of influenza B in Japan
Modification of a SIR dynamic model to a SEIR model for the US and Italy
Dynamic model to inform internal decision making regarding pandemic influenza
Regulatory support for the validation of a questionnaire for influenza vaccination

Measles, mumps and rubella (MMR)

One-pager value communication tool for the measles, mumps and rubella (MMR) vaccine
Payer value deck for an MMR vaccine
e-v@luate platform on vaccines for MMR

Other infectious disease experience

Payer and pricing research and landscape analysis of hygiene product reimbursement and funding flow in UK hospitals for hospital acquired infections
HEOR team capabilities audit and training plan in infectious diseases
Literature review and development of a suite of dossiers in anti-infectives (anti-bacterial resistance)
Development of an e-v@luate EVIDENCE platform for a vaccines portfolio
Literature review of antibiotic resistance
Cost effectiveness analysis model for Portugal on a treatment for bacterial diabetic foot infections
Suite of dossiers for an anti-infective in gram-negative infections
Cost-effectiveness model for cytomegalovirus (CMV) prophylaxis in kidney transplant recipients
Pharmacoeconomic and PRO design and analysis for an immunoglobulin product
Analysis in an EU study in primary immunodeficiency
Pricing reimbursement overview for the UK for a novel anti-viral treatment
Cost effectiveness model on a treatment for bacterial infections
Cost-effectiveness analysis of a treatment of intra-abdominal infections in the USA
Global value dossier, slide deck and FAQs on antibiotic resistance in gram-negative infections
Update to an anti-infectives dossier in gram negative bacterial infections
Estimating the return on investment from investing in adult immunisation in Europe
Strategic access objectives in infectious diseases
Development of a manuscript and consultation on economic evaluations alongside a clinical trial in intra-abdominal infections
Structured literature review and value strategic insight to understand the prevalence and burden of vaccine-preventable diseases (haemophilus influenzae, hepatitis A & B, HPV-associated cancers, influenza, measles, mumps, rubella, meningococcal disease, pneumonia, tetanus, diphtheria, whooping cough, chicken pox, and shingles) amongst sub-populations identified in the ACIP recommendations
Protocol, CRF and distress diary development in infectious diseases
COA consultancy support and validation of a nasal congestion scale

Pertussis

Data review on the burden of pertussis and other infections
Burden of disease literature review on pertussis in the UK and Ireland

Pneumococcal disease

Manuscripts on the health economics of a pneumococcal vaccine
Manuscript on cost-effectiveness analysis in pneumococcal disease
Manuscripts on a vaccine for pneumococcal disease
Payer value deck for pneumococcal disease
Payer value deck for a pneumococcal disease vaccine
Payer communications on pneumococcal disease
Payer communications on a vaccine for pneumococcal disease
Payer material development for vaccines in pneumococcal disease
Responses to payer questions update on a pneumococcal disease vaccine
Update to a one-page value proposition on a pneumococcal disease vaccine
ev@luate platform for vaccine franchises in pneumococcal disease
Payer resources (payer value deck, FAQs and one-pager) for a pneumococcal vaccine
Payer value deck in adult pneumococcal disease (pneumococcal conjugate vaccination)

Pneumonia

Manuscript on a real-world evidence literature review in Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP)
Manuscript and e-v@luate platform in respiratory outcomes for HABP and VABP